Jan 27 (Reuters) - Shares of Geron Corp fell as much as 20 percent after the company said that enrollment had ceased in an early stage trial of its blood cancer drug and that about 20 of 79 patients enrolled in the study had dropped out.
Geron did not say why the patients had dropped out of the trial or if the sponsor, the Mayo Clinic, had stopped the study prematurely. [ID:nEOL9mrWWH]
Geron said the patients in the study would continue to receive the drug and be monitored according to the study design.
Stifel Nicolaus & Co analyst Brian Klein said the limited information that Geron released in a regulatory filing on Monday could call into question the tolerability and durability of the treatment.
"It looks like the therapy for a majority of the patients, or at least a good percentage of the patients, is going to be limited to less than a year," he told Reuters.
Nice post. The insider sales are alarming. Yesterday Schwab reported large insider sales from 5 top officers at NBIX. The news feed is removed or I'd post it. I don't believe those new sales are included in the Yahoo sales you quoted.